ImmunoGen (IMGN) Refines Drug Targeting for Ovarian Cancer Patients (Based on these new findings, ImmunoGen is planning a phase II study of mirvetuximab soravtansin which will enroll ovarian cancer patients with tumors containing medium and high levels of folate receptors. The study is expected to start before the end of the year (mirvetuximab soravtansin)

financial news

..... Based on these new findings, ImmunoGen is planning a phase II study of mirvetuximab soravtansin which will enroll ovarian cancer patients with tumors containing medium and high levels of folate receptors. The study is expected to start before the end of the year.